Twist Bioscience (TWST) has a market capitalization of approximately $5.9B, trading at $95.03 on the NASDAQ. Market cap moves with the live share price.
Twist Bioscience's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 12.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Twist Bioscience runs a net profit margin of -19.8%, a gross margin of 52.1%, and an operating margin of -33.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Twist Bioscience reported revenue of
Twist Bioscience does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Twist Bioscience carries a debt-to-equity ratio of 0.21x and a current ratio of 2.70x, with a market beta of 2.12. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Twist Bioscience (TWST) the key facts are: market cap $5.9B, revenue
Get Twist Bioscience's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.